Emory Saint Joseph's Hospital

Doctors:

Imre Bodo MD

Virginia Critelli MD

Natia Esiashvili MD

Karen D. Godette MD

Bruce W. Hershatter MD

Shannon T. Kahn MD

Jonathan L. Kaufman MD

Mohammad K Khan MD, PhD

Omer Kucuk MD

Gary A. Ludi MD

Peter T. Nieh MD

Jonathan O. Nwiloh MD

John G. Pattaras MD

Satyanarayan K. Reddy MD

Monica Rizzo MD

Seth A Rosen MD

William Holt Sanders MD, FACS

Nikhil L. Shah DO

Joshua Winer MD

Clinical Trials in Georgia

6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type: Unknown Primary

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type: Leukemia, Lymphoma

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

An Internet-Based Application for Improving Adherence to Endocrine Therapy among Patients with Early Stage Hormone Receptor Positive, HER2-Negative Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary

An Investigational Scan (18F-rhPSMA 7.3 PET/CT) with and without Furosemide for the Reduction of Bladder Activity in Patients with Biochemically Recurrent Prostate Cancer
Cancer Type: Prostate Cancer

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Cancer Type: Pancreatic Cancer

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors
Cancer Type: Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary

Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Educational Interview in Improving Health Literacy in African-American Participants with Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET/CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma
Cancer Type: Prostate Cancer , Unknown Primary

Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Cancer Type: Brain & Spinal Cord Tumor

Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cancer Type: Lung Cancer

Stereotactic Radiosurgery or Hippocampus Avoidance Whole-Brain Radiation Therapy with Memantine in Treating Patients with 5 or more Brain Metastases
Cancer Type: Brain & Spinal Cord Tumor, Unknown Primary

TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Cancer Type: Bile Duct Cancer

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Cancer Type: Kidney Cancer

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients with High Risk Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) after Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Cancer Type: Bladder Cancer, Kidney Cancer, Penile Cancer, Urethral Cancer

Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy after Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study
Cancer Type: Bladder Cancer, Unknown Primary

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
Cancer Type: Lung Cancer

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Cancer Type: Neuroendocrine Tumor, Unknown Primary